Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Cheng Website

Y.S. Robert Cheng, D.V.M., Ph.D.

Selected Publications

1)  Cheng RY, Shang Y, Limjunyawong N, Dao T, Das S, Rabold R, Sham JS, Mitzner W, Tang WY.
Alterations of the lung methylome in allergic airway hyper-responsiveness.
Environ. Mol. Mutagen. 55: 244-55, 2014.
2)  Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, Young HA, Trinchieri G, Wink DA.
Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity.
Clin. Cancer Res. 19: 1340-6, 2013.
3)  Basudhar D, Bharadwaj G, Cheng RY, Jain S, Shi S, Heinecke JL, Holland RJ, Ridnour LA, Caceres VM, Spadari-Bratfisch RC, Paolocci N, Velázquez-Martínez CA, Wink DA, Miranda KM.
Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives.
J. Med. Chem. 56: 7804-20, 2013.
4)  Switzer CH, Cheng RY, Ridnour LA, Murray MC, Tazzari V, Sparatore A, Del Soldato P, Hines HB, Glynn SA, Ambs S, Wink DA.
Dithiolethiones inhibit NF-?B activity via covalent modification in human estrogen receptor-negative breast cancer.
Cancer Res. 72: 2394-404, 2012.
5)  Switzer CH, Cheng RY, Ridnour LA, Glynn SA, Ambs S, Wink DA.
Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.
Breast Cancer Res. 14: R125, 2012.
6)  Ridnour LA, Barasch KM, Windhausen AN, Dorsey TH, Lizardo MM, Yfantis HG, Lee DH, Switzer CH, Cheng RY, Heinecke JL, Brueggemann E, Hines HB, Khanna C, Glynn SA, Ambs S, Wink DA.
Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation.
PLoS ONE. 7: e44081, 2012.
7)  Ridnour LA, Dhanapal S, Hoos M, Wilson J, Lee J, Cheng RY, Brueggemann EE, Hines HB, Wilcock DM, Vitek MP, Wink DA, Colton CA.
Nitric oxide-mediated regulation of ß-amyloid clearance via alterations of MMP-9/TIMP-1.
J. Neurochem. 123: 736-49, 2012.
8)  Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, Wink DA.
S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer.
Mol. Cancer Res. 10: 1203-15, 2012.
9)  Switzer CH, Glynn SA, Ridnour LA, Cheng RY, Vitek MP, Ambs S, Wink DA.
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
Trends Pharmacol. Sci. 32: 644-51, 2011.
10)  Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA.
Nitric oxide and redox mechanisms in the immune response.
J. Leukoc. Biol. 89: 873-91, 2011.
11)  Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP.
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
Oncogene. 30: 2504-13, 2011.
12)  Switzer CH, Ridnour LA, Cheng RY, Sparatore A, Del Soldato P, Moody TW, Vitek MP, Roberts DD, Wink DA.
Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity.
Oncogene. 28: 3837-46, 2009.
13)  MacDonald CJ, Cheng RY, Roberts DD, Wink DA, Yeh GC.
Modulation of carcinogen metabolism by nitric oxide-aspirin 2 is associated with suppression of DNA damage and DNA adduct formation.
J. Biol. Chem. 284: 22099-107, 2009.
14)  Bass SE, Sienkiewicz P, Macdonald CJ, Cheng RY, Sparatore A, Del Soldato P, Roberts DD, Moody TW, Wink DA, Yeh GC.
Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.
Clin. Cancer Res. 15: 1964-72, 2009.
15)  Karaczyn AA, Cheng RY, Buzard GS, Hartley J, Esposito D, Kasprzak KS.
Truncation of histone H2A"s C-terminal tail, as is typical for Ni(II)-assisted specific peptide bond hydrolysis, has gene expression altering effects.
Ann. Clin. Lab. Sci. 39: 251-62, 2009.
16)  Tang WY, Newbold R, Mardilovich K, Jefferson W, Cheng RY, Medvedovic M, Ho SM.
Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein.
Endocrinology. 149: 5922-31, 2008.
17)  Bakshi S, Zhang X, Godoy-Tundidor S, Cheng RY, Sartor MA, Medvedovic M, Ho SM.
Transcriptome analyses in normal prostate epithelial cells exposed to low-dose cadmium: oncogenic and immunomodulations involving the action of tumor necrosis factor.
Environ. Health Perspect. 116: 769-76, 2008.
18)  Ciolino H, BASS S, MacDonald C, Cheng R, Yeh G.
Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells.
Intl J of Cancer. 122(5): 990-8, 2007.
19)  Kowara R, Karaczyn A, Cheng RY, Salnikow K, Kasprzak KS.
Microarray analysis of altered gene expression in murine fibroblasts transformed by nickel(II) to nickel(II)-resistant malignant phenotype.
Toxicol. Appl. Pharmacol. 205: 1-10, 2005.
20)  Syed V, Zhang X, Lau KM, Cheng R, Mukherjee K, Ho SM.
Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells.
Oncogene. 24: 8128-43, 2005.
21)  Ho SM, Cheng RY.
A promising bladder cancer detection assay: the HA-HAase test.
J. Urol. 172: 824-5, 2004.
22)  Cheng RY, Hockman T, Crawford E, Anderson LM, Shiao YH.
Epigenetic and gene expression changes related to transgenerational carcinogenesis.
Mol. Carcinog. 40: 1-11, 2004.
23)  Cheng RY, Birely LA, Lum NL, Perella CM, Cherry JM, Bhat NK, Kasprzak KS, Powell DA, Alvord WG, Anderson LM.
Expressions of hepatic genes, especially IGF-binding protein-1, correlating with serum corticosterone in microarray analysis.
J. Mol. Endocrinol. 32: 257-78, 2004.
24)  Lau KM, Tam NN, Thompson C, Cheng RY, Leung YK, Ho SM.
Age-associated changes in histology and gene-expression profile in the rat ventral prostate.
Lab. Invest. 83: 743-57, 2003.
25)  Cheng RY, Zhao A, Alvord WG, Powell DA, Bare RM, Masuda A, Takahashi T, Anderson LM, Kasprzak KS.
Gene expression dose-response changes in microarrays after exposure of human peripheral lung epithelial cells to nickel(II).
Toxicol. Appl. Pharmacol. 191: 22-39, 2003.
26)  Cheng RY, Alvord WG, Powell D, Kasprzak KS, Anderson LM.
Increased serum corticosterone and glucose in offspring of chromium(III)-treated male mice.
Environ. Health Perspect. 110: 801-4, 2002.
27)  Cheng RY, Alvord WG, Powell D, Kasprzak KS, Anderson LM.
Microarray analysis of altered gene expression in the TM4 Sertoli-like cell line exposed to chromium(III) chloride.
Reprod. Toxicol. 16: 223-36, 2002.
28)  Powell DA, Anderson LM, Cheng RY, Alvord WG.
Robustness of the Chen-Dougherty-Bittner procedure against non-normality and heterogeneity in the coefficient of variation.
Journal of biomedical optics. 7: 650-60, 2002.
29)  Ramakrishna G, Sithanandam G, Cheng RY, Fornwald LW, Smith GT, Diwan BA, Anderson LM.
K-ras p21 expression and activity in lung and lung tumors.
Exp. Lung Res. 26: 659-71, 2000.
30)  Zhang DK, Ngan HY, Cheng RY, Cheung AN, Liu SS, Tsao SW.
Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer.
Eur. J. Cancer. 35: 154-60, 1999.
31)  Tsao SW, Zhang DK, Cheng RY, Wan TS.
Telomerase activation in human cancers.
Chin. Med. J. 111: 745-50, 1998.
32)  Cheng RY, Yuen PW, Nicholls JM, Zheng Z, Wei W, Sham JS, Yang XH, Cao L, Huang DP, Tsao SW.
Telomerase activation in nasopharyngeal carcinomas.
Br. J. Cancer. 77: 456-60, 1998.
33)  Cheng R, Lo K, Huang D, Tsao S.
Loss of heterozygosity on chromosome 14 in primary nasopharyngeal carcinoma.
Intl. J. Oncology. 10: 1047-50, 1997.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/8/2014.